Low-Dose Naltrexone and Zolpidem Interaction: What Patients and Clinicians Need to Know

What the naltrexone label says about other drugs

The naltrexone tablet label addresses this only in general terms: 'Studies to evaluate possible interactions between naltrexone hydrochloride and drugs other than opiates have not been performed. Consequently, caution is advised if the concomitant administration of naltrexone hydrochloride and other drugs is required' [1].

The interactions the label does name are opioid-containing medicines, including cough, cold and antidiarrheal products, disulfiram, and thioridazine, where lethargy and somnolence have been reported alongside naltrexone [1]. Zolpidem is not among them, but because interaction studies with non-opioid drugs have not been performed, that is not evidence of compatibility [1].

What the Ambien label says about other drugs

The Ambien label's drug interaction section covers alcohol, opioids, imipramine, chlorpromazine, sertraline, fluoxetine and haloperidol, plus drugs that induce or inhibit CYP3A4; naltrexone is not among them [2]. For sedating drugs, the label says coadministration with other CNS depressants increases the risk of CNS depression, drowsiness and psychomotor impairment including impaired driving, and that dosage adjustments of zolpidem and of the other drug may be necessary [2].

Naltrexone's label describes it as a pure opioid antagonist with few, if any, intrinsic actions besides opioid blockade, and says it is not associated with tolerance or dependence [1].

Sedation and LDN

The naltrexone tablet label lists somnolence (2%) and dizziness (4%) among new-onset reactions in an open-label study of about 570 people with alcoholism taking 50 mg tablets, and reports lethargy and somnolence with thioridazine [1]. Those figures are for the 50 mg tablet, not LDN.

A 2026 narrative review of LDN across chronic pain, autoimmune, gastrointestinal and post-infectious conditions reports mostly mild, transient effects, most often insomnia, vivid dreams, nausea and dizziness [3]. The same review describes the proposed mechanisms behind LDN (TLR4 antagonism on microglia, brief opioid-receptor blockade with compensatory upregulation of endogenous opioid signalling, opioid growth factor receptor effects) as 'largely theoretical and speculative', and concludes that current evidence does not support routine clinical use [3].

Timing and dosing questions

For the 50 mg naltrexone tablet, peak plasma levels occur within an hour of a dose, with a mean half-life of about 4 hours for naltrexone and about 13 hours for its main metabolite, 6-beta-naltrexol [1]. Zolpidem peaks at about 1.6 hours with a half-life of about 2.5 hours [2]. The Ambien label directs that zolpidem be taken once per night immediately before bedtime [2].

LDN dosing is not standardised. A 2026 review describes 0.5 to 6 mg a day, most often 4.5 mg, as off-label, calls the 4.5 mg dose 'empirically derived rather than evidence-based', and notes that inconsistent compounded formulations add uncertainty [3].

Doses the zolpidem label specifies

The recommended initial dose of immediate-release zolpidem is 5 mg for women and 5 or 10 mg for men, taken once per night immediately before bedtime with at least 7 to 8 hours remaining before waking, and it should not be repeated the same night [2]. For elderly or debilitated patients and for patients with mild to moderate hepatic impairment the dose is 5 mg, and the label says to avoid zolpidem in severe hepatic impairment because it may contribute to encephalopathy [2]. The total daily dose must not exceed 10 mg [2].

The label says the risk of next-day psychomotor impairment, including impaired driving, rises with a higher-than-recommended dose, with less than 7 to 8 hours of sleep remaining, and with alcohol or other CNS depressants [2]. FDA says patients can be impaired the next morning even when they feel fully awake [4].

Who the labels flag as higher risk

Adults 65 and older. Beyond the reduced 5 mg dose [2], the 2023 AGS Beers Criteria recommend avoiding zolpidem in older adults (strong recommendation, moderate-quality evidence) because of delirium, falls, fractures and crashes with minimal sleep benefit [5].

Liver impairment. In cirrhosis, zolpidem's peak concentration doubled, total exposure rose fivefold and half-life reached 9.9 hours [2]. Safety data for LDN in liver impairment are sparse [3].

Compromised breathing. The Ambien label says to consider the risk of respiratory depression before prescribing zolpidem to patients with compromised respiratory function [2].

Pregnancy. Zolpidem crosses the placenta; neonates exposed late in the third trimester have had respiratory depression and sedation, some needing ventilation, and published data show no clear link with major birth defects [2]. The naltrexone tablet label states there are no adequate and well-controlled studies in pregnant women and reports early fetal loss in rats at 5 times and rabbits at 18 times the therapeutic dose [1]; the 2026 review describes LDN safety data in pregnancy as sparse [3].

What to watch for

The Ambien label carries a boxed warning for complex sleep behaviours (sleep-walking, sleep-driving and other activities while not fully awake), which can cause serious injury or death and may occur after the first or any later dose, at recommended doses, with or without alcohol or other CNS depressants [2]. The label says to discontinue the drug immediately if such an event occurs, and lists a previous such event as a contraindication [2].

Drowsiness and a decreased level of consciousness make falls more likely, particularly in older patients [2].

One interaction involves both drugs' labels. Naltrexone is contraindicated in patients receiving opioid analgesics, with no dose exception written into that contraindication, and patients taking it may not benefit from opioid-containing cough, cold or antidiarrheal products [1][6]. Separately, the Ambien label says taking zolpidem with opioids may increase the risk of respiratory depression and advises limiting dose and duration of the combination [2].